Identification of Providencia spp. clinical isolates co-producing carbapenemases IMP-27, OXA-24, and OXA-58 in Mexico

Diagn Microbiol Infect Dis. 2024 May;109(1):116246. doi: 10.1016/j.diagmicrobio.2024.116246. Epub 2024 Mar 5.

Abstract

Providencia rettgeri, belonging to the genus Providencia, had gained significant interest due to its increasing prevalence as a common pathogen responsible for healthcare-associated infections in hospitals. P. rettgeri isolates producing carbapenemases have been reported to reduce the efficiency of carbapenems in clinical antimicrobial therapy. However, coexistence with other resistance determinants is rarely reported. The goal of this study was the molecular characterization of carbapenemase-producing Providencia spp. clinical isolates. Among 23 Providencia spp. resistant to imipenem, 21 were positive to blaNDM-1; one positive to blaNDM-1 and blaOXA-58 like; and one isolate co-producing blaIMP-27, blaOXA-24/40 like, and blaOXA-58 like were identified. We observed a low clonal relationship, and the incompatibility groups Col3M and ColRNAI were identified in the plasmid harboring blaNDM-1. We report for the first time a P. rettgeri strain co-producing blaIMP-27, blaOXA-24-like, and blaOXA-58 like. The analysis of these resistance mechanisms in carbapenemase co-producing clinical isolates reflects the increased resistance.

Keywords: Carbapenemase; IMP; Incompatibility; NDM; Providencia.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Bacterial Proteins / genetics
  • Humans
  • Mexico / epidemiology
  • Microbial Sensitivity Tests
  • Providencia* / genetics
  • beta-Lactamases / genetics

Substances

  • carbapenemase
  • Anti-Bacterial Agents
  • beta-Lactamases
  • Bacterial Proteins